Andres Deik1, Rachel Saunders-Pullman. 1. Department of Neurology, Beth Israel Medical Center, New York, New York, USA; University of Pennsylvania, Parkinson Disease and Movement Disorders Center, 330 S. 9th Street, 2nd Floor, Suite 219, Philadelphia, Pennsylvania, 19107, USA.
Abstract
INTRODUCTION: Late-onset Tay-Sachs disease (LOTS) is a lysosomal storage disease caused by deficient Beta-hexosaminidase A activity. METHODS: We describe a 53-year-old woman who presented with adult-onset leg weakness, and whose initial diagnosis was progressive muscular atrophy without identifiable etiology. Development of cerebellar ataxia in mid-life prompted reassessment. RESULTS: Beta-hexosaminidase A quantification assay demonstrated absence of the isozyme. Genetic testing identified compound heterozygous mutations in the HEXA gene, confirming the diagnosis of LOTS. CONCLUSIONS: The phenotypic spectrum of LOTS includes motor neuronopathy, ataxia, choreoathetosis, neuropathy, and psychiatric symptoms in various combinations. This patient highlights the emergence of different clinical features over many years and emphasizes the need to consider LOTS in the differential diagnosis of progressive muscular atrophy.
INTRODUCTION: Late-onset Tay-Sachs disease (LOTS) is a lysosomal storage disease caused by deficient Beta-hexosaminidase A activity. METHODS: We describe a 53-year-old woman who presented with adult-onset leg weakness, and whose initial diagnosis was progressive muscular atrophy without identifiable etiology. Development of cerebellar ataxia in mid-life prompted reassessment. RESULTS:Beta-hexosaminidase A quantification assay demonstrated absence of the isozyme. Genetic testing identified compound heterozygous mutations in the HEXA gene, confirming the diagnosis of LOTS. CONCLUSIONS: The phenotypic spectrum of LOTS includes motor neuronopathy, ataxia, choreoathetosis, neuropathy, and psychiatric symptoms in various combinations. This patient highlights the emergence of different clinical features over many years and emphasizes the need to consider LOTS in the differential diagnosis of progressive muscular atrophy.
Authors: J A P Hiel; B G M van Engelen; C M R Weemaes; A Broeks; A Verrips; H ter Laak; H M Vingerhoets; L P W van den Heuvel; M Lammens; F J M Gabreëls; J I Last; A M R Taylor Journal: Neurology Date: 2006-07-25 Impact factor: 9.910
Authors: Clecio Godeiro-Junior; Andre C Felicio; Vinicius Benites; Marco Antonio Chieia; Acary S B Oliveira Journal: Arq Neuropsiquiatr Date: 2009-03 Impact factor: 1.420
Authors: François Gros-Louis; Nicolas Dupré; Patrick Dion; Michael A Fox; Sandra Laurent; Steve Verreault; Joshua R Sanes; Jean-Pierre Bouchard; Guy A Rouleau Journal: Nat Genet Date: 2006-12-10 Impact factor: 38.330
Authors: P I Rosebush; G M MacQueen; J T Clarke; J W Callahan; P M Strasberg; M F Mazurek Journal: J Clin Psychiatry Date: 1995-08 Impact factor: 4.384
Authors: Z Cao; M R Natowicz; M M Kaback; J S Lim-Steele; E M Prence; D Brown; T Chabot; B L Triggs-Raine Journal: Am J Hum Genet Date: 1993-12 Impact factor: 11.025
Authors: Naiara Akizu; Vincent Cantagrel; Maha S Zaki; Lihadh Al-Gazali; Xin Wang; Rasim Ozgur Rosti; Esra Dikoglu; Antoinette Bernabe Gelot; Basak Rosti; Keith K Vaux; Eric M Scott; Jennifer L Silhavy; Jana Schroth; Brett Copeland; Ashleigh E Schaffer; Philip L S M Gordts; Jeffrey D Esko; Matthew D Buschman; Seth J Field; Gennaro Napolitano; Ghada M Abdel-Salam; R Koksal Ozgul; Mahmut Samil Sagıroglu; Matloob Azam; Samira Ismail; Mona Aglan; Laila Selim; Iman G Mahmoud; Sawsan Abdel-Hadi; Amera El Badawy; Abdelrahim A Sadek; Faezeh Mojahedi; Hulya Kayserili; Amira Masri; Laila Bastaki; Samia Temtamy; Ulrich Müller; Isabelle Desguerre; Jean-Laurent Casanova; Ali Dursun; Murat Gunel; Stacey B Gabriel; Pascale de Lonlay; Joseph G Gleeson Journal: Nat Genet Date: 2015-04-06 Impact factor: 38.330
Authors: Valeriya V Solovyeva; Alisa A Shaimardanova; Daria S Chulpanova; Kristina V Kitaeva; Lisa Chakrabarti; Albert A Rizvanov Journal: Front Physiol Date: 2018-11-20 Impact factor: 4.566
Authors: Olivia E Rowe; D Rangaprakash; Akila Weerasekera; Neha Godbole; Elizabeth Haxton; Peter F James; Christopher D Stephen; Robert L Barry; Florian S Eichler; Eva-Maria Ratai Journal: Mol Genet Metab Date: 2021-06-24 Impact factor: 4.204